ArticleJournal of virology2013
An alphavirus vector-based tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs qualitatively from immunity induced by live virus infection.
Article in Journal of virology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Advancements in dengue vaccines: A historical overview and pro-spects for following next-generation candidates.Journal of microbiology (Seoul, Korea) · 2025Review
- Review
- Approaches of dengue control: vaccine strategies and future aspects.Frontiers in immunology · 2024Review
- Review
- Adenovirus vector-based vaccines as forefront approaches in fighting the battle against flaviviruses.Human vaccines & immunotherapeutics · 2022Review
- Infection order outweighs the role of CD4iScience · 2022Article
- The Delivery of mRNA Vaccines for Therapeutics.Life (Basel, Switzerland) · 2022Review
- Formulation and Delivery Technologies for mRNA Vaccines.Current topics in microbiology and immunology · 2022Article
- Advances in mRNA vaccines.International review of cell and molecular biology · 2022Review
- Immunogenicity of stabilized HIV-1 Env trimers delivered by self-amplifying mRNA.Molecular therapy. Nucleic acids · 2021Article
- mRNA vaccine: a potential therapeutic strategy.Molecular cancer · 2021Review
- A Review on Dengue Vaccine Development.Vaccines · 2020Review
- Challenges in Dengue Vaccines Development: Pre-existing Infections and Cross-Reactivity.Frontiers in immunology · 2020Review
- Time elapsed between Zika and dengue virus infections affects antibody and T cell responses.Nature communications · 2019Article
- Potent neutralizing antibodies elicited by dengue vaccine in rhesus macaque target diverse epitopes.PLoS pathogens · 2019Article
- Development of a Broadly Accessible Venezuelan Equine Encephalitis Virus Replicon Particle Vaccine Platform.Journal of virology · 2018Article
- Recent Developments in Recombinant Protein-Based Dengue Vaccines.Frontiers in immunology · 2018Review
- Use of a Recombinant Gamma-2 Herpesvirus Vaccine Vector against Dengue Virus in Rhesus Monkeys.Journal of virology · 2017Article
- The tetravalent formulation of domain III-capsid proteins recalls memory B- and T-cell responses induced in monkeys by an experimental dengue virus infection.Clinical & translational immunology · 2017Article
- Innovation, urgency and acceptance at the 9th Vaccine Renaissance.Human vaccines & immunotherapeutics · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Despite many years of research, a dengue vaccine is not available, and the more advanced live attenuated vaccine candidate in clinical trials requires multiple immunizations with long interdose periods and provides low protective efficacy. Here, we report important contributions to the development of a second-generation dengue vaccine. First, we demonstrate that a nonpropagating vaccine vector based on Venezuelan equine encephalitis virus replicon particles (VRP) expressing two configurations of dengue virus E antigen (subviral particles [prME] and soluble E dimers [E85]) successfully immunized and protected macaques against dengue virus, while antivector antibodies did not interfere with a booster immunization. Second, compared to prME-VRP, E85-VRP induced neutralizing antibodies faster, to higher titers, and with improved protective efficacy. Third, this study is the first to map antigenic domains and specificities targeted by vaccination versus natural infection, revealing that, unlike prME-VRP and live virus, E85-VRP induced only serotype-specific antibodies, which predominantly targeted EDIII, suggesting a protective mechanism different from that induced by live virus and possibly live attenuated vaccines. Fourth, a tetravalent E85-VRP dengue vaccine induced a simultaneous and protective response to all 4 serotypes after 2 doses given 6 weeks apart. Balanced responses and protection in macaques provided further support for exploring the immunogenicity and safety of this vaccine candidate in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.